DENTSPLY SIRONA (XRAY) vs. Cytori Therapeutics (CYTX) Head to Head Review
DENTSPLY SIRONA (NASDAQ: XRAY) and Cytori Therapeutics (NASDAQ:CYTX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, risk, profitability, valuation and earnings.
This table compares DENTSPLY SIRONA and Cytori Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
DENTSPLY SIRONA has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Cytori Therapeutics has a beta of 2.78, suggesting that its share price is 178% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for DENTSPLY SIRONA and Cytori Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DENTSPLY SIRONA presently has a consensus target price of $65.63, suggesting a potential upside of 6.12%. Cytori Therapeutics has a consensus target price of $3.65, suggesting a potential upside of 630.00%. Given Cytori Therapeutics’ higher probable upside, analysts clearly believe Cytori Therapeutics is more favorable than DENTSPLY SIRONA.
Insider & Institutional Ownership
93.9% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 11.8% of Cytori Therapeutics shares are held by institutional investors. 2.0% of DENTSPLY SIRONA shares are held by company insiders. Comparatively, 1.9% of Cytori Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
DENTSPLY SIRONA pays an annual dividend of $0.35 per share and has a dividend yield of 0.6%. Cytori Therapeutics does not pay a dividend. DENTSPLY SIRONA pays out -10.1% of its earnings in the form of a dividend.
Earnings and Valuation
This table compares DENTSPLY SIRONA and Cytori Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|DENTSPLY SIRONA||$3.84 billion||3.70||$823.80 million||($3.47)||-17.82|
|Cytori Therapeutics||$8.75 million||1.98||-$17.75 million||($1.02)||-0.49|
DENTSPLY SIRONA has higher revenue and earnings than Cytori Therapeutics. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than Cytori Therapeutics, indicating that it is currently the more affordable of the two stocks.
DENTSPLY SIRONA beats Cytori Therapeutics on 12 of the 15 factors compared between the two stocks.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies. The dental industry encompasses the diagnosis, treatment and prevention of disease and ailments of the teeth, gums and supporting bone. Its principal dental product categories are dental consumable products, dental laboratory products, dental specialty products and dental equipment. Additionally, its consumable medical device products are used for urological and surgical applications. These products are produced by the Company in the United States and internationally and are distributed throughout the world under various brand names, including ANKYLOS, AQUASIL ULTRA, ARTICADENT, ATLANTIS, CALIBRA, CAULK, CAVITRON, CELTRA, DELTON, DENTSPLY, DETREY and DYRACT.
About Cytori Therapeutics
Cytori Therapeutics, Inc. (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products. It is focused on developing primary product, Cytori Cell Therapy, for patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence and thermal burns, including those complicated by radiation. Its cellular therapeutics are collectively known by the name, Cytori Cell Therapy, which consists of a heterogeneous population of specialized cells, including stem cells that are involved in response to injury, repair and healing. These cells are extracted from an adult patient’s own adipose tissue using its automated, enzymatic, sterile Celution System devices and consumable sets at the place where the patient is receiving their care.
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.